Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation
European Journal of Cancer · 2025-09 · 227 · 115665
DOI: 10.1016/j.ejca.2025.115665 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025-09. Verfasst von Hanxiao Zuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Scholarship Council, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
BACKGROUND: Early discontinuation of adjuvant endocrine therapy (AET) among patients with estrogen receptor-positive (ER+) breast cancer (BC) is common. Observational studies reported inconsistent effects of early AET discontinuation on survival outcomes, with limited causal evidence. METHODS: We identified women aged 50-80, diagnosed with first primary ER+ BC between 2010-2015, who underwent surgery in Alberta, Canada. The average effect of early AET discontinuation on survival outcomes was estimated by emulating a target trial. Risk factors for early AET discontinuation were evaluated. RESULTS: Of 6823 eligible patients, 21.8 % did not receive AET, 27.3 % discontinued AET within early, and 50.9 % adhered to the 5-year AET. Compared to adhering to 5-year AET, early discontinuation increased the hazard of overall death and recurrence, with greater effects in higher tumor stages. Early discontinuation also significantly increased the risk of breast cancer-specific death (HR=3.92, 95 % CI: 2.96-5.20), but no interaction with tumor stage was observed. No significant difference in survival outcomes was observed between patients discontinuing AET at 4-5 years and those completing 5 years. Older age (>70 years) at diagnosis, lower-stage disease, HER2-negative status, and absence of chemotherapy or radiotherapy were associated with early discontinuation. CONCLUSIONS: Over one-third of ER+ BC patients in our cohort discontinued AET early, which was associated with increased risks of recurrence and mortality. The impact of early discontinuation varied by tumor stage, and one-year reduction in AET duration did not appear to compromise effectiveness. Implementing targeted interventions for ER+ patients may help improve adherence and survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, University of Alberta, Edmonton, AB, Canada.
- Department of Psychology, Queens College, City University of New York, USA.
- University of Alberta, Edmonton, AB, Canada.
- Laboratory Medicine & Pathology Department, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada.
- Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada.
- Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, AB, Canada. Electronic address: kurian.joseph@albertahealthservices.ca.
Förderung
- China Scholarship Council
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Zuo, H., Vaihenberg, E., Singh, A., Bal, G., Bigras, G., Fenton, D., King, K., Yuan, Y., & Joseph, K. (2025). Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation. European Journal of Cancer, 227, 115665. https://doi.org/10.1016/j.ejca.2025.115665
Vancouver
Zuo H, Vaihenberg E, Singh A, Bal G, Bigras G, Fenton D, et al. Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation. European Journal of Cancer. 2025;227:115665. doi:10.1016/j.ejca.2025.115665
BibTeX
@article{Zuo2025,
author = {Zuo, Hanxiao and Vaihenberg, Edward and Singh, Armaan and Bal, Gurniwaz and Bigras, Gilbert and Fenton, David and King, Karen and Yuan, Yan and Joseph, Kurian},
title = {Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation},
journal = {European Journal of Cancer},
year = {2025},
volume = {227},
pages = {115665},
doi = {10.1016/j.ejca.2025.115665}
}
EUVIMED